Global Pharmaceutical Policy

Global Pharmaceutical Policy

Ensuring Medicines for Tomorrow’s World

Frederick M. Abbott and Graham Dukes

Pharmaceuticals play a central role in health care throughout the world. The pharmaceutical industry is beset with difficulties as increasing research and development expenditure yields fewer new treatments. Public and private budgets strain under the weight of high prices and limited access. The world’s poor see little effort to address diseases prevalent in less affluent societies, while the world’s wealthy are overusing prescription drugs, risking their health and wasting resources.

Chapter 10: Global and Regional Policies: The Way Ahead

Frederick M. Abbott and Graham Dukes

Subjects: law - academic, biotechnology and pharmaceutical law


THE WAY AHEAD Worldwide the pharmaceutical sector is currently marked by a series of tensions, which are separate but interlinked and which periodically explode into the public consciousness when acute crises arise. Some of those tensions relate directly to the role of the pharmaceutical industry; others result from the development of public policies that have placed too great a weight on maintaining the status quo rather than working creatively to build a healthy future. This clearly underlies the inherent tension between exclusivity rules in the pharmaceutical market, as promoted in the WTO’s TRIPS Agreement, and the need to provide wider access to medicines. The first major conflict in that connection erupted in South Africa in 2001 and involved a direct but unsuccessful challenge by a group of major pharmaceutical companies to the public health policies of the government.1 Other direct conflicts have occurred in Asia, and the foundations for further conflict are still being laid in the negotiation of ‘Free Trade Agreements’ that, in fact, restrict the ability of developing countries to interpret the TRIPS Agreement in the interest of their own populations. Linked to these problems is widespread discontent with the high level of drug prices, which can render products inaccessible to the poor but can also raise problems in affluent societies. A third source of tension is the increasing realization that useful pharmaceutical innovation has become a rare commodity. Continuing conflict sometimes seems to be an inevitable manifestation of a global system for the development and supply of...

You are not authenticated to view the full text of this chapter or article.

Elgaronline requires a subscription or purchase to access the full text of books or journals. Please login through your library system or with your personal username and password on the homepage.

Non-subscribers can freely search the site, view abstracts/ extracts and download selected front matter and introductory chapters for personal use.

Your library may not have purchased all subject areas. If you are authenticated and think you should have access to this title, please contact your librarian.

Further information